Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally.
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has Protalix BioTherapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PLX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PLX underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: PLX underperformed the US Market which returned 7.1% over the past year.
Price Volatility Vs. Market
How volatile is Protalix BioTherapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StMarket Sentiment Around Loss-Making Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)
4 months ago | Simply Wall StCould The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
5 months ago | Simply Wall StSome Protalix BioTherapeutics (NYSEMKT:PLX) Shareholders Have Taken A Painful 86% Share Price Drop
Is Protalix BioTherapeutics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Protalix BioTherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Protalix BioTherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
- Take a look at our analysis of PLX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Protalix BioTherapeutics regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
How is Protalix BioTherapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if PLX's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if PLX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if PLX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if PLX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PLX's Return on Equity is forecast to be high in 3 years time
How has Protalix BioTherapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PLX is currently unprofitable.
Growing Profit Margin: PLX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PLX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare PLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: PLX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Protalix BioTherapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PLX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PLX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PLX has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: PLX is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.
What is Protalix BioTherapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PLX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PLX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dror Bashan (52yo)
Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019, Mr. Bashan has over 20 years of experience in the pharmaceutical industry wit ...
CEO Compensation Analysis
Compensation vs Market: Dror's total compensation ($USD566.32K) is about average for companies of similar size in the US market ($USD589.04K).
Compensation vs Earnings: Insufficient data to compare Dror's compensation with company performance.
|Founder and Executive VP Research & Development||13.42yrs||US$468.32k||0.25% $282.5k|
|Senior VP||0.67yr||US$369.10k||no data|
|Senior Vice President of Operations||2yrs||US$385.74k||0.062% $70.8k|
|Senior Vice President of Product Development||13.42yrs||US$422.18k||0.057% $65.7k|
|Vice President of Human Resources||9.5yrs||no data||no data|
Experienced Management: PLX's management team is seasoned and experienced (5.8 years average tenure).
|Independent Director||11.83yrs||US$80.00k||0.00052% $598.9|
|Independent Director||5.5yrs||US$80.00k||0.20% $227.2k|
|Director||0.33yr||no data||no data|
|Member of Scientific Advisory Board||3.92yrs||no data||no data|
|Independent Director||1.75yrs||US$80.00k||no data|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||12.75yrs||no data||no data|
|Independent Chairman||0.75yr||US$80.00k||0.67% $767.7k|
|Chairman of Scientific Advisory Board||no data||US$55.00k||no data|
Experienced Board: PLX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PLX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118.6%.
Protalix BioTherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Protalix BioTherapeutics, Inc.
- Ticker: PLX
- Exchange: AMEX
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$115.171m
- Shares outstanding: 32.44m
- Website: https://www.protalix.com
Number of Employees
- Protalix BioTherapeutics, Inc.
- 2 Snunit Street
- Science Park
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PLX||AMEX (NYSE MKT LLC)||Yes||Ordinary Shares||US||USD||Jan 2007|
|PBDA||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 2007|
|PLX||TASE (The Tel-Aviv Stock Exchange)||Yes||Ordinary Shares||IL||ILS||Jan 2007|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/29 02:18|
|End of Day Share Price||2020/05/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.